Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

Leukemia

Volumn 28, Issue 1, 2014, Pages 225-227

  Caocci, G ^a,b   Murgia, F ^a   Podda, L ^c   Solinas, A ^d   Atzeni, S ^a   La Nasa, G ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Binaghi Hospital   (Italy)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; COLLAGEN FIBER; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HYDROXYUREA; JANUS KINASE 1; JANUS KINASE 2; LAMIVUDINE; RETICULIN; RITUXIMAB; RUXOLITINIB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPASSIONATE USE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFECT; ERYTHROID CELL; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOSPLENOMEGALY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MEGAKARYOCYTE; MILIARY TUBERCULOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; NONHODGKIN LYMPHOMA; ORGAN SIZE; PALLIATIVE THERAPY; PATHOGENESIS; POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RISK FACTOR; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION; WEIGHT REDUCTION;

HEPATITIS B; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PYRAZOLES; VIRUS ACTIVATION;

EID: 84891853911     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.235     Document Type: Letter

References (10)

1. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
2. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-1481. (Pubitemid 351615362)
3. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113-121.
4. Pardanani A. Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012; 26: 1449-1451.
5. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
6. Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ. Effect of interferon-g and tumor necrosis factor-a on hepatitis B virus following lamivudine treatment. World J Gastroenterol 2012; 18: 3617-3622.
7. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81: 7351-7362. (Pubitemid 47047824)
8. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.
9. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
10. Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer 2013; 21: 1265-1271.